Wells Fargo & Company MN grew its stake in shares of Ignyta, Inc. (NASDAQ:RXDX) by 2.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,385 shares of the biopharmaceutical company’s stock after acquiring an additional 500 shares during the quarter. Wells Fargo & Company MN owned about 0.05% of Ignyta worth $231,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. American International Group Inc. increased its stake in shares of Ignyta by 7.1% during the 1st quarter. American International Group Inc. now owns 18,148 shares of the biopharmaceutical company’s stock valued at $156,000 after acquiring an additional 1,197 shares during the last quarter. TIAA CREF Investment Management LLC increased its stake in shares of Ignyta by 2.9% during the 1st quarter. TIAA CREF Investment Management LLC now owns 128,339 shares of the biopharmaceutical company’s stock valued at $1,104,000 after acquiring an additional 3,611 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Ignyta by 6.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 61,114 shares of the biopharmaceutical company’s stock worth $526,000 after purchasing an additional 3,946 shares in the last quarter. Legal & General Group Plc increased its position in Ignyta by 71.9% during the 2nd quarter. Legal & General Group Plc now owns 12,681 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 5,306 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Ignyta by 4.5% during the 1st quarter. Geode Capital Management LLC now owns 241,615 shares of the biopharmaceutical company’s stock worth $2,077,000 after purchasing an additional 10,471 shares in the last quarter. 71.82% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Ignyta, Inc. (RXDX) Shares Bought by Wells Fargo & Company MN” was published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/ignyta-inc-rxdx-shares-bought-by-wells-fargo-company-mn/1716996.html.

A number of analysts recently issued reports on the stock. SunTrust Banks, Inc. assumed coverage on shares of Ignyta in a research report on Monday. They set a “buy” rating for the company. Cantor Fitzgerald set a $23.00 target price on shares of Ignyta and gave the stock a “buy” rating in a research report on Tuesday, November 14th. Zacks Investment Research raised shares of Ignyta from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a research report on Tuesday, November 14th. Ladenburg Thalmann Financial Services increased their target price on shares of Ignyta from $20.25 to $31.00 in a research report on Wednesday, October 18th. Finally, J P Morgan Chase & Co reissued a “buy” rating and set a $20.00 target price (up previously from $18.00) on shares of Ignyta in a research report on Thursday, October 12th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Ignyta has a consensus rating of “Buy” and a consensus price target of $23.80.

Shares of Ignyta, Inc. (NASDAQ RXDX) opened at $15.75 on Tuesday. Ignyta, Inc. has a 1 year low of $4.60 and a 1 year high of $18.30. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.34.

Ignyta (NASDAQ:RXDX) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.03. equities research analysts forecast that Ignyta, Inc. will post -2.31 earnings per share for the current fiscal year.

Ignyta Company Profile

Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.

Want to see what other hedge funds are holding RXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ignyta, Inc. (NASDAQ:RXDX).

Institutional Ownership by Quarter for Ignyta (NASDAQ:RXDX)

Receive News & Ratings for Ignyta Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.